CA Patent

CA2588296A1 — Composition comprising an nmda receptor antagonist and levodopa and use thereof for treating neurological disease

Assigned to Adamas Pharmaceuticals Inc · Expires 2006-06-01 · 20y expired

What this patent protects

The invention provides methods and compositions for treating or preventing neurological disorders.

USPTO Abstract

The invention provides methods and compositions for treating or preventing neurological disorders.

Drugs covered by this patent

amantadine-hydrochloride (AMANTADINE HYDROCHLORIDE)

Patent Metadata

Patent number: CA2588296A1
Jurisdiction: CA
Classification: —
Expires: 2006-06-01
Drug substance claim: No
Drug product claim: No
Assignee: Adamas Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.